Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03455270
Title G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | BGR | BEL


No variant requirements are available.